Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and innovation is our passion. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.
In view of our vision of a world free of pain, Grünenthal strives to provide effective medication to patients worldwide. Therefore, we continuously grow and expand our market presence and product portfolio, and we collaborate with commercial partners and multiple stakeholders from the pain management field and beyond.
At Grünenthal, conducting our business responsibly is a core part of our company’s strategy and culture. As a global leader in pain management, Grünenthal aspires to create a positive impact for society – in our core business and beyond. We are guided by integrity, transparency and the highest ethical standards.
We follow a holistic and solution-agnostic approach to deliver highly effective pain treatments, building our programmes on a firm foundation of human pathophysiology and solid human target validation.
Grünenthal is a global leader in pain management and related diseases. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain. Explore our recent stories to see what drives us.
Aachen/Brussels, 23 June 2016. For the tenth time, young European scientists who have an innovative pain research idea, are called upon to apply for one of the most prestigious and highly regarded pain research grants worldwide: The EFIC-GRÜNENTHAL Grant (E-G-G).
Aachen, Germany, and Pisa, Italy – 16 December 2016 – Grünenthal, an R&D-driven, privately held international pharmaceutical company with headquarters in Germany, and Abiogen Pharma, privately held Italian pharmaceutical company with headquarter in Pisa, Italy announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to neridronic acid, an investigational medicine, for the treatment of complex regional pain syndrome (CRPS), a serious, disabling orphan disease.
Quito, Ecuador and Aachen, Germany. December 14, 2016. The Grünenthal Group announces today that its manufacturing site in Ecuador, Tecnandina, successfully passed the inspection to manufacture in accordance with the European GMP regulations. The certification covers the production of solid and semi-solid pharmaceuticals for the third time and now, for the first time, also liquid pharmaceuticals. This GMP Certificate will be valid for another three years.
Aachen, December 12, 2016. Grünenthal Group today announced that it has entered into a definitive agreement with Astellas Pharma Europe Ltd., (“Astellas Pharma Europe”), the European subsidiary of Tokyo-based Astellas Pharma Inc. (“Astellas”), for the exclusive rights to the dermal patch Qutenza® (capsaicin 8%) in Europe, Middle East and Africa. Qutenza® is approved by the European Medicines Agency (EMA) for the treatment of peripheral neuropathic pain (PNP).
Aachen, Germany, and Pittsburgh, PA, USA – 16 November 2016 – Grünenthal, an R&D-driven, privately held international pharmaceutical company with headquarters in Germany, has announced its recent acquisition of Thar Pharmaceuticals, a US-based clinical-stage, specialty pharmaceutical company. Thar Pharmaceuticals focused on transforming IV-only drugs into oral drugs for existing and new indications using its proprietary technology EnhanceTM development platform. With this acquisition, Grünenthal has obtained the worldwide development and commercialization rights for Thar Pharmaceutical’s lead development candidate, T121.
Aachen, Germany, October 4, 2016. The Grünenthal Group today announces that Gabriel Baertschi has taken office as new CEO of the Grünenthal Group, an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. The company’s Supervisory Board had named Gabriel Baertschi to become Grünenthal’s new CEO in June 2016. Gabriel Baertschi is joining Grünenthal from AstraZeneca, a global, science-led biopharmaceutical business where in his last appointment he served as country president for Japan. He succeeds Prof. Dr. Eric-Paul Pâques who retires at the end of 2016 after 23 years at Grünenthal.
Yokohama, Japan, September 30, 2016 - Grünenthal presents data for the first time of its compound cebranopadol in patients with cancer-related pain1. The cebranopadol data is from a Phase 3 randomized, double-blind, double-dummy, active-controlled multiple dose study with patients randomized to either once-daily cebranopadol or twice-daily morphine sulfate PR (prolonged release). Results reached statistical significance for non-inferiority and even superiority for the primary endpoint (average amount of daily rescue medication intake over the last two weeks of the maintenance phase in the trial, p<0.05).
Aachen, Germany, September 27, 2016. The LifeSciences.NRW called for consortia of small and medium-sized companies and academic groups within North Rhein-Westphalia to compete in making proposals for developing solutions to solve current challenges within the field of biomedical sciences. Of the 51 submissions, the project of the consortium under the direction of Grünenthal was also considered worthy of funding.
Aachen, Germany, June 7, 2016 – Grünenthal Group today announced that its Supervisory Board has named Gabriel Baertschi to become Grünenthal’s new CEO as of October 1, 2016. Gabriel Baertschi will join Grünenthal from AstraZeneca, a global, science-led biopharmaceutical business where he currently serves as country president for Japan. He succeeds Prof. Dr. Eric-Paul Pâques, who has been the CEO of the Grünenthal Group. Grünenthal is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany with affiliates in Europe, Latin America and the U.S. In 2015, Grünenthal achieved revenues of € 1.2 bn.
Aachen, June 2, 2016. Grünenthal Group today announced that it has entered into a licensing agreement with AstraZeneca for the exclusive rights to Zurampic™ (lesinurad) in Europe and Latin America. Zurampic™ was approved by the European Medicines Agency (EMA) in February 2016, in combination with a xanthine oxidase inhibitor (XOI), for the treatment of adjunctive hyperuricemia in adult patients with uncontrolled gout.
Aachen, Germany, May 11, 2016. The Grünenthal Group today announced an exclusive license and supply agreement with Adhesys Medical Inc., USA, on the commercialization of an innovative topical skin adhesive. With this agreement, Grünenthal acquires the exclusive distribution rights for the EU and Latin American markets. Both companies pursue the common objective to launch a medical device that meets highest standards.
Aachen, Germany and Mexico City, Mexico, March 15, 2016. Grünenthal Group announced today to have entered into a definitive agreement with Almirall Group under which Grünenthal will acquire 100% of the share capital of Almirall de Mexico. The transaction also includes an agreement to perpetually license a portfolio of mainly international products with around 17.5 million Euro net sales in 2015 in Mexico. The transaction will be completed in early May, 2016.
Aachen, Germany and Milano, Italy, March 3, 2016: Grünenthal and Axxam announced today that they have entered into an integrated collaboration. The objective is to discover novel small molecule lead structures for the development of pain and inflammation therapeutics by combining Axxam’s drug discovery platform with Grünenthal’s expertise on emerging and innovative biological pathways and targets.
DURHAM, N.C. – February 22, 2016 – Patheon, the leading global provider of pharmaceutical development and manufacturing services today announced it has signed a strategic agreement with Grünenthal, an independent, family-owned, international research-based pharmaceutical group headquartered in Aachen, Germany to serve as its preferred development partner for its products made using Grünenthal’s innovative abuse deterrent formulation technology INTAC®.
Aachen, February 10, 2016 – The Grünenthal Group announced today the completion and inauguration of its new research building on the Grünenthal Campus in Aachen. It will accommodate room for 150 employees working in research and development. Thus Grünenthal again commits to its headquarters in Aachen and to researching and developing of innovative medicines to the benefits of patients. The annual Research & Development expenditures of the group have constantly been well above the pharmaceutical industry’s average for years in relation to sales.
Aachen, Germany, and Cambridge, MA, USA, January 8, 2016 – Grünenthal today announced the joint global drug development program with Akashi Therapeutics, Inc., for HT-100, an orally available small molecule drug candidate designed to reduce fibrosis and inflammation and to promote healthy muscle fiber regeneration in Duchenne Muscular Dystrophy (DMD) patients. The drug has orphan designation in both the U.S. and the EU, and fast track designation in the U.S.
Aachen, Germany, and Leiden, the Netherlands, January 6, 2016 – The Grünenthal Group, an international, family-owned pharmaceutical company, announced today the opening of an Innovation Hub as an expansion of its Innovative Medicines Unit. The Hub will be located in Leiden, the Netherlands, and be embedded in the Leiden Bio Science Park, the largest cluster of biotech and pharmaceutical companies in the Netherlands and one of the five most successful science parks in Europe.